Why we're cautious about 2015: Germany's Merck By: CNBC.com News March 03, 2015 at 04:10 AM EST Stiff competition for its biggest drug and high research and development costs have pushed Merck to adopt a cautious outlook, the German firm said. Read More >> Related Stocks: Biogen Idec Pfizer Sanofi-Aventis S.A. ADR Sigma-Aldrich